Cardinal Health stock extends CVS deal through 2032

Published on 10/06/2026 at 17:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cardinal Health stock reflects a CVS distribution extension through June 30, 2032, announced October 1, 2026. Fiscal 2026 revenue rose 14 percent to USD 254.2 billion.

CGI-Render moderner Unternehmensgebäude mit Glasfassade und Außenanlage in Dublin Ohio — Architektur-Render des Cardinal Health Inc. Hauptsitzes in Dublin, Ohio – ISIN US14149Y1082, Illustration mit AI erstellt.

Cardinal Health stock was trading at USD 232.84 on the NYSE at 11:54 a.m. ET on October 6, 2026, down 0.12 percent from USD 233.12. The company has extended its pharmaceutical distribution agreement with CVS Health through June 30, 2032, giving the stock a concrete contract backdrop.

CVS agreement protects distribution scope

According to Cardinal Health on October 1, 2026, the binding letter of intent keeps the existing scope of services for CVS Health in place through June 30, 2032. The release also reaffirmed fiscal 2027 non-GAAP EPS guidance of USD 12.40 to USD 12.60, representing growth of 13 percent to 15 percent.

The agreement supports revenue visibility, but it does not represent a change in the current service scope. Cardinal Health said further updates may come with its first-quarter fiscal 2027 earnings call on November 5, 2026, according to the same October 1 release from Cardinal Health.

Fiscal 2026 delivered double digit growth

The latest reported year provides the operating comparison behind the guidance. As Yahoo Finance reported for the August 11, 2026 release, fiscal 2026 revenue increased 14 percent to USD 254.2 billion from USD 222.6 billion.

Fiscal 2026 non-GAAP diluted EPS rose 37 percent to USD 11.26, while GAAP diluted EPS reached USD 7.23 versus USD 6.45 in fiscal 2025. Fourth-quarter revenue increased 6 percent to USD 63.7 billion, and fourth-quarter non-GAAP diluted EPS increased 40 percent to USD 2.91.

The growth mix was not uniform. Fourth-quarter Pharmaceutical and Specialty Solutions revenue rose 6 percent to USD 58.8 billion, while Global Medical Products and Distribution revenue declined 2 percent to USD 3.1 billion, according to the company results carried by Yahoo Finance. That contrast makes specialty execution and distribution volume important checkpoints for the November report.

Analysts see upside above the stock

According to MarketBeat, 16 analysts rate Cardinal Health Buy and 3 rate it Hold, producing a Moderate Buy consensus and an average target of USD 266.56. The average target lies 14.5 percent above the USD 232.84 reference price.

The same MarketBeat report lists recent targets of USD 260 from Bank of America, USD 270 from Evercore, USD 275 from Barclays and USD 277 from Wells Fargo, compared with the current share price. The target spread reflects continued optimism, while the guidance range keeps the November earnings release as the next material test.

Cardinal Health stock holds a wide range

Cardinal Health stock was last at USD 232.84 on October 6, 2026, with a session range of USD 231.65 to USD 234.53. Its 52-week range is USD 151.87 to USD 258.30, and the market capitalization is USD 54.5 billion.